GDPD3 and chronic myelogenous leukemia, BCR-ABL1 positive: Disease relapse was significantly decreased in treated recipients bearing Gdpd3−/− retro-CML-LSK cells compared to those that received Gdpd3+/+ retro-CML-LSK cells (Fig. 6a).